Although alternative gating strategies can be applied (eg, based on CD10, CD34, and/or CD45), you could also choose to add CD24 and/or CD22 to the current tubes (transforming it into a 10-color tube) in MRD-based tests involving Blinatumomab. 43Addition of CD24 and CD22 may also have the benefit that the first BCP cells, expressing CD24 and/or CD22 but not yet CD19, 44can be discovered; this may be of relevance pertaining to the recognition of all BCP cells in regenerating BM samples. In order to obtain MRD data with good level of sensitivity, acquisition of large numbers of cells seems to be a prerequisite. BCP cells in 99% of researched patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone tissue marrow followup samples of 178 BCP-ALL individuals. Comparison with RQ-PCRbased MRD data demonstrated a clear positive relation between percentage concordant cases and the number of cells acquired. For all those samples with > four million cells acquired, concordant results were acquired in 93% of examples. Most discordances were cleared up upon high-throughput sequencing of antigen-receptor rearrangements and sightless multicenter reanalysis of circulation cytometric data, resulting in an unprecedented concordance of 98% (97% Bis-NH2-PEG2 pertaining to samples with MRD < 0. 01%). To conclude, the fully standardized EuroFlow BCP-ALL MRD strategy is applicable in > 98% of patients with sensitivities in least just like RQ-PCR (105), if enough cells (> 4 106, preferably more) are evaluated. == Advantages == Most current treatment protocols for B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) include minimal residual disease (MRD) measurements, generally based on polymerase string reaction (PCR) analysis of rearranged antigen receptor genes. 1-3Although circulation cytometry (FCM) can be used pertaining to MRD detection as well, 4-9studies so Bis-NH2-PEG2 far show that the specificity and level of sensitivity of FCM-MRD diagnostics are inferior to PCR-based MRD diagnostics. 10-13Nevertheless, we while others have recently shown the use of 6- or 7-color immunostainings combined with the introduction of new markers and new marker combinations considerably improved FCM-MRD analysis in BCP-ALL individuals. 10, 12These improvements were particularly associated with specificity, whereas the level of sensitivity still appeared to be Amotl1 lower than pertaining to the PCR-based methods. To further improve FCM-based MRD diagnostics, more objective and efficient discrimination of BCP-ALL cells coming from normal BCP cells and improved sample preparation methods for acquisition of larger numbers of cells really are a prerequisite. Eight-color immunostainings might contribute to improve flow cytometric MRD detection in BCP-ALL patients. Recently, an 8-color antibody tube was developed in the ALL-REZ-BFM 2002 trial. 14This tube comprised 7 antibodies (CD10, CD19, CD20, CD22, CD34, CD45, CD38) and the nucleic acid solution dye Syto41 and gave concordant MRD results with PCR-MRD data in 86. 5% of samples. A Chinese research reported an 8-color antibody tube (CD10, CD19, CD20, CD34, CD38, CD45, CD58, plus CD66c or CD13/CD33 or NG2/CD15) with a level of sensitivity of 0. 001% in 81. 6% of individuals. 8Shaver ainsi que al elegantly analyzed the relative contribution that each marker and/or pair of markers made to detect MRD15and concluded that a single 8-color tube consisting of CD9, CD10, CD19, CD20, CD34, CD38, CD45, and CD58 could offer as much diagnostic utility as their existing 3-tube panel with 12 markers. Within the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708), we aimed to design standardized 8-color immunophenotyping protocols for multicenter MRD measurement in BCP-ALL and to improve the sensitivity in the assay to 105(at least comparable to PCR). First, in order to select the most informative markers in differentiating BCP-ALL coming from normal BCP cells, we applied book software tools and principal component-based analyses. sixteen, 17In each cycle of design-test-evaluate-redesign, the antibody tubes were tested on BCP-ALL samples and normal and/or regenerating bone tissue marrow (BM), followed by examination of the contribution of each antibody, until acceptable results were acquired after five testing rounds. Second, a flow cytometric protocol pertaining to staining and acquisition of large numbers of cells (> 4 million) was developed, permitting theoretical sensitivities of in least 0. 001% (105). Finally, the selected antibody tubes and standardized Bis-NH2-PEG2 laboratory methods were prospectively validated upon follow-up examples from BCP-ALL patients, using the EuroMRD PCR-MRD methods in parallel since gold regular. 2 == Materials and methods == == BCP-ALL patients and normal settings == Data were collected in 7 EuroFlow centers. BM examples obtained from healthful donors or patients in whom simply no hematological malignancy could be recognized (eg, BM samples submitted for lymphoma staging, neuroblastoma staging) were used since control BM for normal/reactive BCP cells. BM examples obtained from pediatric ALL individuals after induction therapy (day 78 of therapy) or 1 year after stop of therapy, proven to be MRD-negative by real-time quantitative polymerase string reaction (RQ-PCR) analysis, were used like a source of regenerating BCP. In the first section of the study (panel design and optimization), examples from 319 BCP-ALL individuals, which were consecutively received during 5 design-test-evaluate-redesign phases (initial phase: and = 69; phase 1: n = 61; phase 2: and =.